Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19
| Autor: | Zhijian Cao, Xugang Li, Wanhong Liu, Yingliang Wu, Fang Sun, Jean-Marc Sabatier, Cédric Annweiler, Yingqiu Xie, Jiyuan Xu, Chenglin Mu, Hang Fai Kwok |
|---|---|
| Přispěvatelé: | Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS) |
| Rok vydání: | 2021 |
| Předmět: |
MESH: Virus Internalization
viruses Akt inhibitor Applied Microbiology and Biotechnology Chlorocebus aethiops AKT inhibitor Phosphatidylinositol 3-Kinases MESH: Chlorocebus aethiops Neoplasms MESH: COVID-19 MESH: Animals MESH: Neoplasms skin and connective tissue diseases biology integumentary system 3. Good health [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology antiviral activity MESH: Pyrroles Research Paper 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Proto-Oncogene Proteins c-akt Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) MESH: Receptor Cross-Talk MESH: Vero Cells capivasertib MESH: Computer Simulation Animals Humans MESH: SARS-CoV-2 Computer Simulation Pyrroles Molecular Biology Vero Cells Ecology Evolution Behavior and Systematics MESH: Humans MESH: Proto-Oncogene Proteins c-akt SARS-CoV-2 fungi COVID-19 Cell Biology Receptor Cross-Talk Virus Internalization biology.organism_classification Virology COVID-19 Drug Treatment body regions PI3K/AKT pathway Pyrimidines MESH: Pyrimidines [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology Vero cell Commentary [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Developmental Biology |
| Zdroj: | International Journal of Biological Sciences International Journal of Biological Sciences, Ivyspring International Publisher, 2021, 17 (9), pp.2348-2355. ⟨10.7150/ijbs.57810⟩ International Journal of Biological Sciences, 2021, 17 (9), pp.2348-2355. ⟨10.7150/ijbs.57810⟩ |
| ISSN: | 1449-2288 |
| Popis: | International audience; Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|